



Applied Research Departments

5

Cardiovascular Translational Research





Applied Research Departments

5 Cardiovascular Translational Research

The TCR department is the nexus between the CNIC and the hospital system, facilitating collaboration between clinical research groups and the CNIC's scientists, encouraging the application and clinical testing of new technologies, and training clinical researchers.

Fixed-dose combination therapy for cardiovascular prevention: The CNIC Polypill Project



Head of Laboratory: *Ginés Sanz*

Project Manager: *Luz Álvarez*

Administrative Support: *Laura González Betlinski*



RESEARCH INTEREST

During 2010 we carried out the clinical phase of the project. Most of the planned studies have been completed, and demonstrate the safety and tolerability of the polypill. Participants are now being recruited for the study of pharmacodynamic interaction with simvastatin (350 patients) and we expect to have results by the end of 2011.

The polypill registration dossier has been presented in several countries in Central and South America, and marketing of the drug has been already approved in Guatemala.

The kick-off meeting for the FOCUS study was held in Madrid last June and the inclusion of patients will be in May 2011. FOCUS is a European Union (FP7) funded project which will test the efficacy of the polypill in a population of more than 1300 patients in five countries: Argentina, Brazil, Italy, Paraguay and Spain. The study, led by Dr. Valentin Fuster, is coordinated by the Department of Translational Cardiovascular Research.



MAJOR GRANTS

- Ministerio de Ciencia e Innovación. FIS (PI07/0773)
- European Commission FP7 (241559 FOCUS)



SELECTED PUBLICATIONS

Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, García EJ, López-Sendón JL, Macaya C, Hernández-Antolín R; TRIANA Investigators. **Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies.** *Eur Heart J* (accepted)

García-Alvarez A, Sitges M, Pinazo MJ, Regueiro-Cueva A, Posada E, Poyatos S, Ortiz-Pérez JT, Heras M, Azqueta M, Gascon J, Sanz G. **Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage.** *PLoS Negl Trop Dis* (2010) 4: e826

García-García C, Sanz G, Valle V, Molina L, Sala J, Subirana I, Martí H, Marrugat J, Bruguera J, Masià R, Elosua R. **Trends in in-hospital mortality and six-month outcomes in patients with a first acute myocardial infarction. Change over the last decade.** *Rev Esp Cardiol* (2010) 63: 1136-44

Rígol M, Solanes N, Farré J, Roura S, Roqué M, Berrueto A, Bellera N, Novensà L, Tamborero D, Prat-Vidal C, Huzman MA, Batlle M, Hoefsloot M, Sitges M, Ramírez J, Dantas AP, Merino A, Sanz G, Brugada J, Bayés-Genís A, Heras M. **Effects of adipose tissue-derived stem cell therapy after myocardial infarction: impact of the route of administration.** *J Card Fail* (2010) 16: 357-66

Jansà M, Hernández C, Vidal M, Nuñez M, Bertran MJ, Sanz S, Castell C, Sanz G. **Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital.** *Patient Educ Couns* (2010) 81: 161-8